Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 1.
CATAPRES vs CATAPRES-TTS-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance and lowered blood pressure.
Alpha-2 adrenergic agonist that reduces sympathetic outflow from the CNS, leading to decreased peripheral vascular resistance and blood pressure.
Oral: 0.1 mg twice daily initially, titrate to 0.2-0.6 mg/day in divided doses; maximum 2.4 mg/day. Transdermal: 0.1 mg/24 hours patch applied every 7 days, titrate to 0.2-0.3 mg/24 hours.
Clonidine transdermal system 0.1 mg/24 hours applied to intact skin on upper arm or chest once every 7 days. Titrate based on response, maximum 0.3 mg/24 hours.
None Documented
None Documented
Terminal elimination half-life: 12-16 hours in normal renal function; prolonged to 48-96 hours in severe renal impairment. Use with caution in CKD.
12-16 hours; may be prolonged in renal impairment (up to 40 hours).
Renal: ~65% (40-50% unchanged; 20-25% as metabolites). Biliary/fecal: ~35% (conjugated metabolites).
Renal: 40-60% unchanged; biliary/fecal: ~20% as metabolites; remainder metabolized.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist